BRPI1016109A2 - "composto, composição farmacêutica, e, processo para preparar um composto" - Google Patents
"composto, composição farmacêutica, e, processo para preparar um composto"Info
- Publication number
- BRPI1016109A2 BRPI1016109A2 BRPI1016109A BRPI1016109A BRPI1016109A2 BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2 BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A BRPI1016109 A BR PI1016109A BR PI1016109 A2 BRPI1016109 A2 BR PI1016109A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparing
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21853909P | 2009-06-19 | 2009-06-19 | |
| PCT/GB2010/051003 WO2010146395A1 (en) | 2009-06-19 | 2010-06-17 | Pyrazine carboxamides as inhibitors of dgat1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1016109A2 true BRPI1016109A2 (pt) | 2016-05-17 |
Family
ID=42357808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1016109A BRPI1016109A2 (pt) | 2009-06-19 | 2010-06-17 | "composto, composição farmacêutica, e, processo para preparar um composto" |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8188092B2 (pt) |
| EP (1) | EP2443096A1 (pt) |
| JP (1) | JP2012530122A (pt) |
| KR (1) | KR20120037939A (pt) |
| CN (1) | CN102498103A (pt) |
| AR (1) | AR077140A1 (pt) |
| AU (1) | AU2010261499A1 (pt) |
| BR (1) | BRPI1016109A2 (pt) |
| CA (1) | CA2764013A1 (pt) |
| MX (1) | MX2011014018A (pt) |
| RU (1) | RU2011152517A (pt) |
| TW (1) | TW201103895A (pt) |
| UY (1) | UY32716A (pt) |
| WO (1) | WO2010146395A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197926A1 (en) * | 2006-06-08 | 2009-08-06 | Alan Martin Birch | Benzimidazoles and their use for the treatment of diabetes |
| WO2011121350A1 (en) | 2010-04-01 | 2011-10-06 | Astrazeneca Ab | 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors |
| EP2684879A1 (en) | 2012-07-09 | 2014-01-15 | Basf Se | Substituted mesoionic compounds for combating animal pests |
| EP2903985A1 (en) | 2012-10-03 | 2015-08-12 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Ｆｌａｐ調節劑 |
| JP6424173B2 (ja) | 2013-02-04 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｆｌａｐ調節因子 |
| CN103467392B (zh) * | 2013-10-09 | 2016-08-17 | 重庆工商大学 | 一种多卤代吡嗪甲酰胺衍生物及其盐类、制备方法和用途 |
| CN103880757B (zh) * | 2014-04-15 | 2016-02-24 | 上海毕得医药科技有限公司 | 一种5-羟基嘧啶-2-羧酸的合成方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3245989A (en) | 1962-12-15 | 1966-04-12 | Acraf | 3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles |
| US4983731A (en) | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
| IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
| US5491172A (en) | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
| GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
| US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| US6608185B1 (en) | 1999-03-25 | 2003-08-19 | Kitasato Institute | Substances KF-1040T4A,KF-1040T4B, KF-1040T5A, and KF-1040T5B, and process for producing same |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| JP2002284741A (ja) | 2001-03-23 | 2002-10-03 | Kitasato Inst:The | ローズリピン誘導体 |
| DE50208960D1 (de) | 2001-08-31 | 2007-01-25 | Sanofi Aventis Deutschland | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar-aktivatoren |
| DE10223273A1 (de) | 2002-05-24 | 2003-12-04 | Aventis Pharma Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20090286791A1 (en) | 2001-11-27 | 2009-11-19 | Takeda Pharmaceutical Company Limited | Amide Compounds |
| FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
| WO2003105209A1 (ja) * | 2002-06-06 | 2003-12-18 | 関西ティー・エル・オー株式会社 | 太陽電池用多結晶シリコン基板の製造方法 |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| HRP20050022A2 (en) | 2002-07-12 | 2006-03-31 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| AU2003265659A1 (en) | 2002-08-23 | 2004-03-11 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| JP2006503081A (ja) | 2002-10-10 | 2006-01-26 | スミスクライン ビーチャム コーポレーション | 化学化合物 |
| AU2003293006A1 (en) | 2002-11-22 | 2004-06-18 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
| SG2012000667A (en) | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| WO2004089927A1 (en) | 2003-04-07 | 2004-10-21 | Cortical Pty Ltd | Novel methods for the treatment of inflammatory diseases |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| MXPA05012281A (es) | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
| WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| US20050143464A1 (en) | 2003-09-22 | 2005-06-30 | Use-Techno Corporation | Insulin secretion potentiator |
| JP4956191B2 (ja) | 2003-10-17 | 2012-06-20 | インサイト コーポレーション | マトリックスメタロプロテイナーゼの阻害剤としての置換環状ヒドロキサメート |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| US20050101660A1 (en) | 2003-11-11 | 2005-05-12 | The Skinny Drink Company | Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| AU2005209115A1 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| WO2006004200A1 (ja) | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| MX2007004217A (es) | 2004-10-15 | 2007-06-11 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de obesidad. |
| WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
| WO2006064189A1 (en) | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
| WO2006082952A1 (ja) | 2005-02-01 | 2006-08-10 | Takeda Pharmaceutical Company Limited | アミド化合物 |
| CA2596639A1 (en) | 2005-02-07 | 2006-08-10 | F. Hoffmann-La Roche Ag | Inhibitors of diacylglycerol acyltransferase (dgat) |
| JP2008536947A (ja) | 2005-04-19 | 2008-09-11 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | アリールアルキル酸誘導体およびそれらの使用 |
| JP2008540485A (ja) | 2005-05-10 | 2008-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | ジアシルグリセロールアシルトランスフェラーゼ阻害剤 |
| MX2007015759A (es) | 2005-06-11 | 2008-02-21 | Astrazeneca Ab | Derivados de oxadiazol como inhibidores de diacilglicerol aciltransferasa (dgat). |
| WO2007007588A1 (ja) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | 平面性を有する環状基を母核とする化合物 |
| CN101583352A (zh) | 2005-07-29 | 2009-11-18 | 拜尔健康护理有限责任公司 | 治疗肥胖症的联苯氨基酸衍生物的制备和用途 |
| JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
| WO2007060140A2 (en) | 2005-11-28 | 2007-05-31 | F. Hoffmann-La Roche Ag | Inhibitors of diacyglycerol acyltransferase (dgat) |
| JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
| EP1966221A1 (en) | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
| WO2007074753A1 (ja) | 2005-12-27 | 2007-07-05 | Daiichi Sankyo Company, Limited | 置換されたウレア誘導体を含有する医薬 |
| AU2007245059B2 (en) * | 2006-03-31 | 2011-07-28 | Novartis Ag | New compounds |
| EP2016047B1 (en) | 2006-04-21 | 2013-08-28 | Eli Lilly And Company | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 |
| US20080064717A1 (en) | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| US20080015227A1 (en) | 2006-05-19 | 2008-01-17 | Kym Philip R | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
| CN101460470B (zh) | 2006-05-30 | 2011-05-18 | 阿斯利康(瑞典)有限公司 | 作为dgat1抑制剂的1,3,4-二唑衍生物 |
| EP2041100B1 (en) | 2006-05-30 | 2010-12-22 | AstraZeneca AB | Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
| CN101460469A (zh) | 2006-06-06 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 化合物 |
| US20090197926A1 (en) | 2006-06-08 | 2009-08-06 | Alan Martin Birch | Benzimidazoles and their use for the treatment of diabetes |
| GB0611506D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611507D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| US20120065196A1 (en) | 2006-07-21 | 2012-03-15 | Shuji Kitamura | Amide compounds |
| US7569590B2 (en) | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
| KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
| KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| AU2007304365A1 (en) | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| CA2668744C (en) | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| BRPI0719352A2 (pt) | 2006-11-29 | 2017-10-24 | Abbott Lab | inibidores de enzima diacilglicerol o-aciltransferase tipo 1 |
| MX2009006171A (es) | 2006-12-11 | 2009-06-19 | Novartis Ag | Metodo para la prevencion o el tratamiento de isquemia de miocardio. |
| EP2142521A1 (en) | 2007-04-30 | 2010-01-13 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| JP2010536839A (ja) | 2007-08-17 | 2010-12-02 | アストラゼネカ アクチボラグ | 化合物９７９ |
| KR20100099738A (ko) * | 2007-12-20 | 2010-09-13 | 아스트라제네카 아베 | Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190 |
| JP2010132590A (ja) | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
| JP2012512860A (ja) | 2008-12-19 | 2012-06-07 | アストラゼネカ アクチボラグ | １，３，４−オキサジアゾール誘導体および糖尿病を処置するそれらの使用 |
-
2010
- 2010-06-17 EP EP10725494A patent/EP2443096A1/en not_active Withdrawn
- 2010-06-17 WO PCT/GB2010/051003 patent/WO2010146395A1/en not_active Ceased
- 2010-06-17 KR KR1020127001363A patent/KR20120037939A/ko not_active Withdrawn
- 2010-06-17 MX MX2011014018A patent/MX2011014018A/es not_active Application Discontinuation
- 2010-06-17 JP JP2012515565A patent/JP2012530122A/ja active Pending
- 2010-06-17 CN CN201080036012XA patent/CN102498103A/zh active Pending
- 2010-06-17 UY UY0001032716A patent/UY32716A/es unknown
- 2010-06-17 CA CA2764013A patent/CA2764013A1/en not_active Abandoned
- 2010-06-17 RU RU2011152517/04A patent/RU2011152517A/ru unknown
- 2010-06-17 AU AU2010261499A patent/AU2010261499A1/en not_active Abandoned
- 2010-06-17 TW TW099119725A patent/TW201103895A/zh unknown
- 2010-06-17 BR BRPI1016109A patent/BRPI1016109A2/pt not_active Application Discontinuation
- 2010-06-18 US US12/818,187 patent/US8188092B2/en not_active Expired - Fee Related
- 2010-06-18 AR ARP100102161A patent/AR077140A1/es unknown
-
2012
- 2012-04-25 US US13/455,275 patent/US20120289520A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010146395A1 (en) | 2010-12-23 |
| KR20120037939A (ko) | 2012-04-20 |
| AU2010261499A1 (en) | 2012-01-12 |
| US20120289520A1 (en) | 2012-11-15 |
| US8188092B2 (en) | 2012-05-29 |
| EP2443096A1 (en) | 2012-04-25 |
| UY32716A (es) | 2011-01-31 |
| TW201103895A (en) | 2011-02-01 |
| RU2011152517A (ru) | 2013-07-27 |
| CN102498103A (zh) | 2012-06-13 |
| JP2012530122A (ja) | 2012-11-29 |
| AR077140A1 (es) | 2011-08-03 |
| CA2764013A1 (en) | 2010-12-23 |
| MX2011014018A (es) | 2012-02-22 |
| US20100324068A1 (en) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
| BRPI1006162A2 (pt) | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". | |
| BRPI0910734A2 (pt) | composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo. | |
| BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
| BRPI0811712A2 (pt) | "composto, processo de preparação de um composto e composição farmacéutica". | |
| BR112013008008A2 (pt) | composto, composição farmacêutica e processo para preparar um composto | |
| BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
| BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI1010128A2 (pt) | "processo para a fabricação do 2,3,3,3 - tetrafluropropeno" | |
| BRPI1011888A2 (pt) | processo para preparar um composto, e, composição. | |
| BRPI0905847A2 (pt) | "composição farmacêutica injetável e processo para preparar a composição" | |
| BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' | |
| BRPI0815784A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
| BRPI1010933A2 (pt) | processo para a preparação de um pó, e, composto | |
| BRPI1014547A2 (pt) | composto, e, processo para preparar um composto. | |
| BRPI0911897A2 (pt) | Processo para a preparação de compostos, e, composto | |
| BRPI1014691A2 (pt) | Composto, e, processo para a preparação de um composto. | |
| BRPI0922714A2 (pt) | composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica | |
| BRPI1016109A2 (pt) | "composto, composição farmacêutica, e, processo para preparar um composto" | |
| BRPI0815971A2 (pt) | Processo para a preparação de 1,2-propanodiol | |
| BRPI0813772A2 (pt) | Composto, processo para a preparação de um composto, e, conjugado | |
| BRPI1007654A2 (pt) | composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |